HealthCap is a Stockholm-based venture capital firm focused on investments in multi-stage life sciences companies.
Business Model:
Revenue: $0
Employees: 0-0
Address: Engelbrektsplan 1
City: Stockholm
State: södermanlands län
Zip: 114 34
Country: SE
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2011 | BONESUPPORT | Venture Round | 18.6M |
7/2005 | OxThera | Venture Round | 21M |
7/2000 | Cytos | Series B | 32M |
4/2015 | Idea | Venture Round | - |
12/2012 | Ultragenyx Pharmaceutical | Series B | 75M |
10/2016 | BONESUPPORT | Venture Round | 36.1M |
2/2015 | Altimmune | Post-IPO Equity | 16M |
6/2017 | Carisma Therapeutics | Seed Round | - |
2/2005 | Five Prime Therapeutics | Series C | 45M |
6/2012 | BONESUPPORT | Venture Round | 10M |
7/2007 | Immune Targeting Systems | Series A | 7.1M |
9/2010 | Cardoz | Series A | 17.6M |
12/2001 | Gyros | Series B | 29.5M |
6/2004 | ChemoCentryx | Series B | 33M |
9/2006 | Resistentia Pharmaceuticals | Series C | 14M |
4/2010 | Oncos Therapeutics | Series C | 5.5M |
11/2006 | BONESUPPORT | Venture Round | 19.5M |
6/2004 | Jerini | Series B | 38M |
6/2020 | Doctrin | Series B | 8.9M |
10/2014 | Strongbridge Biopharma | Venture Round | 11M |
2/2005 | Jerini | Venture Round | 20.2M |
1/2021 | Aro Biotherapeutics | Series A | 88M |
1/2011 | Nexstim | Venture Round | 0 |
11/2018 | Precirix | Series A | 41.9M |
7/2015 | GenSight Biologics | Series B | 0 |
8/2005 | Alba Therapeutics | Series A | 30M |
4/2014 | Wilson Therapeutics | Series B | 40M |
6/2021 | Doctrin | Series C | 0 |
10/2008 | ChemoCentryx | Series E | 50M |
11/2008 | Tengion | Series C | 0 |
4/2019 | Fusion Pharmaceuticals | Series B | 0 |
4/2002 | Dynavax Technologies | Series D | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
5/2018 | Rainier Therapeutics | Series B | 20M |
9/2007 | Nexstim | Venture Round | 10.9M |
8/2003 | BioStratum | Venture Round | 9.5M |
3/2021 | Carisma Therapeutics | Series B | 0 |
3/2003 | Sopherion Therapeutics | Series A | 0 |
4/2015 | LTB4 Sweden | Venture Round | - |
1/2015 | Strongbridge Biopharma | Venture Round | 27.5M |
1/2004 | PTC Therapeutics | Series E | 35M |
4/2023 | ADCendo | Series A | 0 |
11/2006 | Abionyx Pharma | Series B | 53.5M |
1/2005 | Biolipox | Series C | 41M |
12/2014 | Glionova | Series A | 5.7M |
9/2001 | PTC Therapeutics | Series D | 0 |
11/2006 | CoreValve | Venture Round | 20M |
2/2023 | Spruce Biosciences | Post-IPO Equity | 0 |
11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
11/2018 | InCarda Therapeutics | Series B | 42M |
1/2003 | Biolipox | Series B | 21M |
7/2005 | CoreValve | Series B | 24M |
12/2001 | Hybrigenics | Series B | 11.6M |
2/2017 | Fusion Pharmaceuticals | Series A | 0 |
7/2002 | Direct Conversion | Series B | 21M |
12/2017 | Doctrin | Venture Round | 0 |
12/1998 | OraPharma Inc. (acquired by JNJ) | Venture Round | 16M |
6/2004 | PTC Therapeutics | Series E | 0 |
7/2011 | SpineVision | Venture Round | 0 |
10/2007 | Tengion | Series C | 33M |
10/2000 | Arpida AG | Series B | 22.3M |
6/2006 | Tengion | Series B | 50M |
7/2018 | Modus Therapeutics | Series A | 15.8M |
2/2020 | Spruce Biosciences | Series B | 88M |
2/2023 | Hemab | Series B | 0 |
9/2017 | Fusion Pharmaceuticals | Series A | 0 |
10/2020 | Priothera | Series A | 0 |
1/2003 | Orexo | Series B | 22.4M |
7/2021 | Hemab | Series A | 0 |
7/2010 | Abionyx Pharma | Series C | 0 |
8/2003 | Renovis | Series E | 45M |
6/2004 | Nucleonics | Series B | 49.2M |
9/2005 | Algeta | Series A | 28.9M |
3/2007 | CoreValve | Series C | 33M |
6/2011 | Ultragenyx Pharmaceutical | Series A | 45M |
6/2007 | OxThera | Venture Round | 0 |
12/2001 | Pharmion | Venture Round | 65M |
12/2021 | Oncorena | Venture Round | 0 |
10/2021 | HelloBetter | Series A | 0 |
8/2005 | Abionyx Pharma | Series A | 30.5M |
3/2010 | Immune Targeting Systems | Series A | 13.2M |
11/2009 | FerroKin Biosciences | Venture Round | 15M |
3/2022 | HelloBetter | Series A | 0 |
9/2009 | BeneChill | Series C | 13.5M |
6/2010 | FerroKin Biosciences | Series B | 12M |
8/2005 | Tengion | Series A | 39M |
5/1998 | Actelion Pharmaceuticals | Venture Round | 12M |
9/2004 | Sopherion Therapeutics | Series B | 47M |
3/2022 | Precirix | Series B | 0 |
4/2021 | ADCendo | Series A | 61.8M |
5/2023 | HelloBetter | Series A | 0 |
11/2018 | Aprea | Series C | 0 |
9/2022 | Pretzel Therapeutics | Series A | 0 |
1/2021 | Carisma Therapeutics | Series B | 0 |
6/2018 | Carisma Therapeutics | Series A | 0 |
9/2022 | Carisma Therapeutics | Series C | 0 |
3/2017 | Rainier Therapeutics | Series B | 30M |
5/2017 | Vivet Therapeutics | Series A | 41.2M |
3/2010 | Pulmonx | Series C | 0 |
10/2020 | InCarda Therapeutics | Series C | 30M |
6/2017 | Tisbury Pharmaceuticals | Series A | 32M |
11/2021 | Elsa | Seed Round | 4.4M |
11/2018 | Oncorena | Venture Round | 1.6M |
12/2002 | Renovo | Series B | 33M |
4/2014 | Rainier Therapeutics | Series A | 6M |
6/2000 | Hybrigenics | Series A | 8.5M |
3/2016 | Aprea | Series B | 50.6M |
8/2019 | Carisma Therapeutics | Series A | 6M |
1/2016 | Rainier Therapeutics | Series A | 13M |
6/2009 | Lumavita | Series A | 5.5M |
7/2003 | Bionaut Pharmaceuticals | Series A | 6.8M |
6/2022 | Ariceum Therapeutics | Series A | 0 |
3/2022 | Precirix | Series B | 0 |
3/2022 | HelloBetter | Series A | 0 |
12/2021 | Oncorena | Venture Round | 0 |
11/2021 | Elsa | Seed Round | 0 |
10/2021 | HelloBetter | Series A | 0 |
7/2021 | Hemab | Series A | 0 |
6/2021 | Doctrin | Series C | 0 |
4/2021 | ADCendo | Series A | 0 |
3/2021 | Carisma Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|